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Psychotropic drugs are used for treatment of behavioral and psychological symptoms of
dementia (BPSD) although they are associated with serious adverse drug events. Objective
of our study was to investigate prevalence of psychotropic drug use one year after diagnoses of
Alzheimer's disease (AD), to compare prevalence to persons without AD and to assess changes in
prevalence over time. Data from the MEDALZ (Medication use and Alzheimer's disease) cohort
was utilized in the study including all 69,080 community-dwelling persons with new diagnosis of
AD during years 2005–2011 in Finland. Four age-, gender- and region of residence-matched
persons without AD were identiﬁed for each case. Register-based data included prescription
drug purchases and comorbidities from Special Reimbursement Register. Annual prevalence of
psychotropic drug use one year after diagnosis was determined for each person. Psychotropic
drugs were used by 53% of persons with AD compared with 33% of persons without AD during one
year after diagnoses. Persons with AD were six times more likely to use antipsychotics and three
times more likely to use antidepressants whereas benzodiazepine and related drug (BZDR) use
was comparable between persons with and without AD. According to year of AD diagnoses
during 2005–2011, antipsychotic use increased from 18% to 20% (po0.0001) and BZDR use
declined from 31% to 26% (po0.0001) among persons with AD. Widespread utilization of
psychotropic drugs was observed among persons with AD. Despite safety warnings ofo.2014.10.004
CNP. This is an open access article under the CC BY-NC-ND license
/by-nc-nd/3.0/).
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Psychotropic drugs are used in the treatment of behavioral
and psychological symptoms of dementia (BPSD) in persons
with Alzheimer's disease (AD) (Finnish Medical Society
Duodecim, 2010). Antidementia drugs are recommended
as the ﬁrst-line treatment for BPSD. Treatment with psy-
chotropic drugs is recommended only for most severe
symptoms and for short-term use if non-pharmacological
options are not effective.
Psychotropic drugs have been associated with serious
adverse drug events among older persons and persons with
dementia. Antipsychotics have been linked to an increased
risk of stroke (Mittal et al., 2011). All psychotropic drugs
have been associated with falls and hip fractures (Cumming
and Le Couteur, 2003; Hartikainen et al., 2007; Coupland
et al., 2011; Oderda et al., 2012; Xing et al., 2014). Studies
regarding the risk of death associated with psychotropic drug
use have been inconclusive. Numerous studies indicate the
association between antipsychotic use and an increased
mortality risk (Schneider et al., 2005; Wang et al., 2005;
Schneeweiss et al., 2007; Ballard et al., 2009; Kales et al.,
2012; Gerhard et al., 2014) with some conﬂicting results
(Gardette et al., 2012; Lopez et al., 2013), whereas anti-
depressant (Ried et al., 2011; Coupland et al., 2011) and
benzodiazepine studies (Kripke et al., 1998; Gisev et al.,
2011) show mixed results. Antipsychotic and benzodiazepine
use has been associated with decline in cognition (Hanlon
et al., 1998; Byerly et al., 2001; Paterniti et al., 2002) which
counteracts the main goals in the treatment of AD including
preservation of cognitive function and delay of institutiona-
lization (Finnish Medical Society Duodecim, 2010).
Few previous studies have investigated psychotropic drug use
in persons with incident dementia. Martinez et al. (2013)
determined prescribed prevalence of psychotropic drug use at
the time of dementia diagnoses during 1995–2011. Schulze
et al. (2013a) determined prevalence of antipsychotic use in
the year of dementia incidence and studied the impact of
safety warnings on prevalence of antipsychotic use (Schulze
et al., 2013b). Franchi et al. (2012) investigated changes in
antipsychotic use after the safety warnings among persons
prescribed with acetylcholinesterase inhibitors. There is a lack
of studies concerning prevalence of psychotropic drug use at
the time of clinically veriﬁed diagnosis of Alzheimer's disease
compared with matched comparison persons. Objective of our
study was to investigate the prevalence of psychotropic drug
use one year after diagnosis of Alzheimer's disease, to compare
the prevalence with persons without AD and to assess changes
in prevalence between persons diagnosed in 2005–2011.
2. Experimental procedures
Data from the MEDALZ (Medication use and Alzheimer's disease)
cohort was utilized in the study. The MEDALZ cohort consists of all73,005 persons diagnosed with AD between 2005 and 2011 in Finland.
Four age-, gender- and region of residence-matched persons without
AD were identiﬁed from database including all residents, leading to
the cohort of 365,011 persons. Persons without AD were chosen
based on not having diagnoses of AD or antidementia drug purchases
at the index date (date of AD diagnosis for the case) or 12 months
after that. Furthermore, non-AD person needed to be alive and not in
long-term care facility during the month of AD diagnosis for the case.
During the follow-up, some persons in non-AD group developed AD
(N=14,343), and they were deﬁned as AD cases and four comparison
persons were identiﬁed as described.
Persons with AD were identiﬁed from the Special Reimbursement
Register which includes data on entitlement to special reimbursement
of drugs based on clinically diagnosed chronic diseases. Identiﬁcation
of AD cases and registers is described in more detail in Tolppanen et al.
(2013). In short, the Finnish Current Care Guideline recommends that
all persons with AD are treated with antidementia drugs unless there is
a contraindication for the use (Finnish Medical Society Duodecim,
2010). Persons with probable AD need a veriﬁed diagnosis completed
according to an exact diagnostic protocol monitored by the Social
Insurance Institution to be entitled to reimbursed antidementia drugs.
The veriﬁed AD diagnosis includes computed tomography or magnetic
resonance imaging scan, and conﬁrmation of the diagnosis by a
neurologist or geriatrician. The special reimbursement for AD medica-
tion is not withdrawn when AD progresses to severe stage. Diagnosis of
AD was based on the NINCDS–ADRDA (McKhann et al., 1984) and DSM-IV
criteria (American Psychiatric Association, 1994).
Data of the MEDALZ cohort has been linked to several nationwide
registers including Prescription Register (1995–2012), Special Reim-
bursement Register (1972–2012), Register of Care at Social Institu-
tions (1995–2012), and Hospital Discharge Register (1972–2012).
Prescription Register includes information on all purchases of
prescribed and reimbursed drugs categorized according to Anato-
mical Therapeutic Chemical – classiﬁcation system (ATC) (WHO,
2014). Data were de-identiﬁed before submission to the research
team and thus, no ethics committee approval was required.
In this study, psychotropic drug purchases one year after index date
(i.e. the date of AD diagnosis) were extracted (annual prevalence).
The index date of the case was determined as starting date for 12
months follow-up period for comparison persons. Antipsychotics were
deﬁned as ATC class N05A excluding lithium. Atypical antipsychotics
were deﬁned as ziprasidone, clozapine, olanzapine, quetiapine,
risperidone, aripiprazole, asenapine and paliperidone, and other drugs
in N05A (excluding lithium) were classiﬁed as conventional antipsy-
chotics (chlorpromazine, levomepromazine, dixyrazine, perphenazine,
periciazine, thioridazine, haloperidol, melperone, sertindole, ﬂupen-
tixol, chlorprothixene, zuclopenthixol, pimozide, and sulpiride). Anti-
depressants were deﬁned as N06A and further categorized as tricyclic
antidepressants (N06AA), selective serotonin reuptake inhibitors
(SSRIs) (N06AB) and other antidepressants (N06AX). Benzodiazepines
and related drugs (BZDRs) were deﬁned as N05BA, N05CD and N05CF.
BZDRs were further classiﬁed as benzodiazepines (BZDs) (N05BA and
N05CD) and Z-drugs (N05CF). Most commonly purchased drug sub-
stances were calculated for each psychotropic drug class and sepa-
rately among persons with and without AD. One person may have
purchased several drugs during the follow-up and thus, contributed to
several substances.
For the present study, persons were excluded if they were in
long-term care for over 240 days of the year after AD diagnosis
1731High prevalence of psychotropic drug use among persons with and without Alzheimer's diseasebecause drugs used in long-term care are not available in the
Prescription Register. Persons with dementia related to Parkinson's
disease are also granted special reimbursement for antidementia
drugs. These persons were excluded from the present study.
Exclusions are described in more detail in Figure 1.Table 1 Annual prevalence of psychotropic drug use
during one year after diagnoses of AD in MEDALZ data.
Drug group Persons
with AD
Persons
without AD
N=69,080 N=275,021
Users % (N) Users % (N)
Antipsychotics 20% 4% (10,492)2.1. Statistical analysis
Descriptive statistical analyses were undertaken using means,
standard deviations (SD) and percentages. All analyses included
annual prevalence data one year after the index date. Prevalence
between cases and controls was compared with logistic regression
with odds ratios (ORs) and 95% conﬁdence intervals (CIs). Preva-
lence of psychotropic drug use between persons diagnosed in
different years was compared with logistic regression to prevalence
of those diagnosed in 2005. Trend in prevalence in 2005–2011 was
modelled as year being a continuous variable and tested with
Cochran–Armitage Trend test. Age was measured at the index date.
Use of two or more psychotropic drugs was deﬁned as use of
antipsychotics, antidepressants and BZDRs. All analyses were per-
formed using SAS (version 9.3; SAS Institute Inc., Cary, NC, USA).(13,628)
Conventional
antipsychotics
2.5% (1740) 1.4% (3714)
Atypical antipsychotics 18.2%
(12,588)
2.8% (7555)
Antidepressants 28%
(19,296)
11% (31,416)
Tricyclic antidepressants 0.9% (617) 1.5% (4101)
SSRIs 17.9%
(12,392)
6.1% (16,815)
Other antidepressants 11.9%
(8198)
5.0% (13,790)
Benzodiazepines and
related drugs
29%
(20,251)
27% (73,740)
Benzodiazepines 16.9%
(11,690)
13.1% (35,964)
Z-drugs 15.7%
(10,857)
16.3% (44,737)3. Results
The study population consisted of 69,080 persons with AD and
275,021 persons without AD. Mean age of persons with and
without AD was 80 years (SD 7.1 years), and 65% were female.
During one year after AD diagnoses, 53% of persons with
AD purchased at least one psychotropic drug. Antipsychotics
were utilized by 20%, antidepressants by 28% and BZDRs by
29% of persons with AD (Table 1). At least two psychotropic
drugs were purchased by 20% of persons with AD.
During the one year follow-up time, 33% of persons
without AD purchased at least one psychotropic drug and
8% had purchased at least two psychotropics. Antipsychotics
were used by 4%, antidepressants by 11% and BZDRs by 27%
of persons without AD (Table 1).
Persons with AD used all psychotropic drug classes more
frequently than persons without AD (Table 2). Persons withFigure 1 Flow chart of exclusions based on dementia relatedAD were six times more likely to use antipsychotics and
three times more likely to use antidepressants than persons
without AD. More frequent utilization of psychotropic drugs was
observed among genders and in all age groups. Only exception
was BZDR use among persons aged Z85 years with whom no
difference was found between persons with and without AD.
Antipsychotic use slightly increased from 2005 to 2011 when
prevalence was compared between years of AD diagnoses in
persons with AD (Figure 2). In contrast to antipsychotic use,to Parkinson's disease and long-term care in the MEDALZ data.
Table 2 Comparison of psychotropic drug use among persons with and without AD in MEDALZ data.
Drug Persons with AD N=69,080 Persons without
AD N=275,021
Odds ratio (95% CI)
Antipsychotic use 20% (13,628) 4% (10,492) 6.20 (6.03–6.37)
Men 18%(4396) 3% (2954) 7.03 (6.69–7.38)
Women 21% (9232) 4% (7538) 5.88 (5.69–6.07)
o65 years 21% (480) 3% (308) 7.66 (6.58–8.92)
65–74 years 19% (2359) 3% (1446) 7.87 (7.35–8.43)
75–84 years 19% (7270) 4% (5363) 6.44 (6.20–6.68)
Z85 years 22% (3519) 5% (3375) 4.97 (4.72–5.22)
Antidepressant use 28% (19,296) 11% (31,416) 3.01 (2.95–3.07)
Men 22% (5300) 8% (7765) 3.20 (3.08–3.33)
Women 31% (13,996) 13% (23,651) 2.97 (2.90–3.04)
o65 years 33% (748) 11% (954) 4.21 (3.77–4.70)
65–74 years 29% (3503) 9% (4405) 4.07 (3.87–4.28)
75–84 years 28% (10,525) 11% (17,025) 3.02 (2.94–3.11)
Z85 years 28% (4520) 14% (9032) 2.35 (2.25–2.44)
Benzodiazepine and related drug use 29% (20,251) 27% (73,740) 1.13 (1.11–1.15)
Men 26% (6260) 21% (19,823) 1.35 (1.31–1.39)
Women 31% (13,991) 30% (53,917) 1.05 (1.03–1.07)
o65 years 22% (498) 13% (1208) 1.84 (1.64–2.06)
65–74 years 25% (3021) 19% (9369) 1.39 (1.33–1.46)
75–84 years 30% (11,285) 27% (41,729) 1.10 (1.08–1.14)
Z85 years 33% (5447) 33% (21,434) 1.00 (0.97–1.04)
H. Taipale et al.1732BZDR use declined and antidepressant use remained stable.
Among persons without AD, prevalence of antipsychotic and
antidepressant use remained stable whereas BZDR use
increased during 2005–2008 and then declined to somewhat
lower level than observed in 2005. Antipsychotic use increased
according to year of diagnoses in 2008–2011 by 10–20% com-
pared to those diagnosed in 2005 (Table 3). In 2008, antipsy-
chotic use started to increase whereas BZDR use started to
decline compared to those diagnosed in 2005. Among persons
without AD, antipsychotic use declined and antidepressant use
slightly increased in 2006–2011 compared to year 2005. In both
persons with and without AD, SSRI use declined whereas use of
other antidepressants increased during the follow-up. Similarly
in both groups, conventional antipsychotic use declined and
atypical antipsychotic use increased.
The most frequently purchased antipsychotics among
persons with and without AD were risperidone and quetia-
pine (Table 4). Among antidepressants, most commonly
purchased drugs were mirtazapine, citalopram and escita-
lopram among groups. Among persons without AD, amitrip-
tyline was more commonly used antidepressant compared to
persons with AD. Most frequently used BZDRs were zopi-
clone, temazepam and oxazepam among groups. Lorazepam
was ranked as the fourth most common BZDR among persons
with AD whereas zopiclone among persons without AD. In
addition, the prevalence of diazepam use was higher among
persons without AD compared to persons with AD.
Among psychotropic drug prescribers, non-specialized
physicians accounted for 48–60% of the ﬁrst prescriptions of
psychotropic drug classes. The prescriptions stated by spe-
cialized physicians were further analyzed according to pre-
scribers' specialty. Among persons with AD, general
practitioners were the most common prescribers (41% of
antipsychotic, 41% of antidepressant and 57% of BZDRprescriptions). Geriatricians followed the GPs representing
26% of antipsychotic, 26% of antidepressant and 15% of BZDR
prescriptions. Third ranked prescriber specialty was neurol-
ogists (14% of antipsychotic, 14% of antidepressant and 6% of
BZDR prescriptions) whereas psychiatrist was the fourth most
common prescribers (7% of antipsychotics, 5% of antidepres-
sants and 5% of BZDRs). The prescriber rankings were similar
among persons without AD except that percentage of general
practitioners was higher (varied from 56% of antipsychotics to
65% of BZDRs) and psychiatrists were ranked the second most
common prescribers of antipsychotics (18%).4. Discussion
In our study, psychotropic drugs were more frequently used
by persons with AD compared to persons without AD. Over
half of persons with AD used at least one psychotropic drug
during one year after diagnosis and they were six times
more likely to use antipsychotics and three times more
likely to use antidepressants compared to persons without
AD. According to year of AD diagnosis during 2005–2011, we
found an increasing trend of antipsychotic use whereas
BZDR use declined among persons with AD.
We found higher prevalence of antipsychotic use (20%)
one year after AD diagnoses compared to a previous study
(13%) that included persons with all types of dementia
diagnoses (Martinez et al., 2013). One study reported higher
prevalence (25%) of antipsychotic drug use among persons
with dementia during one year after diagnoses but they
included also persons living in institutional care (Schulze
et al., 2013a). In their study, prevalence of antipsychotic
use was 11% among community-dwelling persons without
need for long-term care services. Thus, prevalence of
Figure 2 Changes in prevalence of psychotropic drug use according to year of AD diagnoses. (A) antipsychotics,
(B) benzodiazepines and related drugs, (C) conventional antipsychotics, (D) benzodiazepines, (E) atypical antipsychotics,
(F) Z-drugs, (G) antidepressants, (H) tricyclic antidepressants, (I) SSRIs, and (J) other antidepressants.
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Table 3 Prevalence of psychotropic drug use during one year after diagnoses of Alzheimer's disease according to diagnoses year in persons with Alzheimer's disease.
Prevalence 2006 OR (95% CI) 2007 OR (95% CI) 2008 OR (95% CI) 2009 OR (95% CI) 2010 OR (95% CI) 2011 OR (95% CI) p-Value for trenda
Persons with AD
Antipsychotic use 1.01 (0.94–1.09) 1.06 (0.98–1.14) 1.12 (1.04–1.21) 1.14 (1.06–1.23) 1.19 (1.10–1.27) 1.09 (1.01–1.17) o0.0001
Typicals 1.00 (0.85–1.18) 0.75 (0.63–0.89) 0.70 (0.59–0.83) 0.68 (0.57–0.81) 0.64 (0.53–0.76) 0.43 (0.36–0.52) o0.0001
Atypicals 1.01 (0.93–1.09) 1.12 (1.03–1.21) 1.20 (1.11–1.30) 1.22 (1.13–1.32) 1.30 (1.20–1.40) 1.22 (1.14–1.32) o0.0001
Antidepressant use 1.01 (0.94–1.08) 1.04 (0.98–1.12) 1.06 (0.99–1.13) 1.04 (0.97–1.11) 1.04 (0.97–1.10) 1.02 (0.96–1.09) 0.5070
Tricyclics 0.86 (0.64–1.15) 0.74 (0.55–0.99) 0.75 (0.56–1.00) 0.70 (0.52–0.93) 0.74 (0.56–0.99) 0.66 (0.49–0.88) 0.0037
SSRIs 0.94 (0.87–1.02) 0.99 (0.92–1.06) 0.95 (0.88–1.02) 0.88 (0.82–0.95) 0.85 (0.79–0.92) 0.80 (0.74–0.86) o0.0001
Other antidepressants 1.16 (1.05–1.30) 1.19 (1.07–1.31) 1.29 (1.17–1.42) 1.42 (1.29–1.56) 1.50 (1.37–1.65) 1.57 (1.44–1.72) o0.0001
Benzodiazepine and related drug use 1.01 (0.95–1.08) 0.96 (0.90–1.03) 0.93 (0.88–0.99) 0.89 (0.83–0.94) 0.87 (0.81–0.92) 0.76 (0.72–0.81) o0.0001
Benzodiazepines 1.03 (0.95–1.11) 0.94 (0.87–1.01) 0.88 (0.81–0.94) 0.83 (0.77–0.90) 0.77 (0.71–0.83) 0.71 (0.66–0.76) o0.0001
Z-drugs 1.00 (0.92–1.08) 0.98 (0.91–1.06) 0.99 (0.91–1.07) 0.95 (0.88–1.03) 0.97 (0.89–1.05) 0.85 (0.79–0.92) o0.0001
Persons without AD
Antipsychotic use 0.85 (0.78–0.92) 0.88 (0.82–0.95) 0.89 (0.83–0.96) 0.88 (0.82–0.95) 0.86 (0.79–0.92) 0.92 (0.86–0.99) 0.1458
Typicals 0.80 (0.71–0.89) 0.73 (0.65–0.82) 0.59 (0.53–0.67) 0.53 (0.47–0.60) 0.51 (0.45–0.57) 0.47 (0.41–0.52) o0.0001
Atypicals 0.88 (0.80–0.97) 1.00 (0.91–1.10) 1.10 (1.01–1.21) 1.13 (1.03–1.24) 1.11 (1.02–1.22) 1.26 (1.16–1.37) o0.0001
Antidepressant use 1.05 (1.00–1.11) 1.04 (0.99–1.09) 1.05 (1.01–1.10) 1.06 (1.01–1.11) 1.11 (1.06–1.16) 1.11 (1.06–1.16) o0.0001
Tricyclics 1.04 (0.92–1.17) 0.96 (0.85–1.08) 0.94 (0.83–1.05) 0.85 (0.75–0.95) 0.85 (0.75–0.96) 0.89 (0.79–0.99) o0.0001
SSRIs 1.04 (0.98–1.11) 0.97 (0.92–1.03) 0.94 (0.89–1.00) 0.88 (0.83–0.94) 0.89 (0.84–0.94) 0.87 (0.82–0.92) o0.0001
Other antidepressants 1.08 (0.99–1.16) 1.20 (1.11–1.29) 1.30 (1.21–1.40) 1.50 (1.38–1.59) 1.64 (1.53–1.76) 1.67 (1.56–1.79) o0.0001
Benzodiazepine and related drug use 1.06 (1.02–1.10) 1.05 (1.02–1.09) 1.11 (1.08–1.15) 1.10 (1.06–1.14) 1.04 (1.01–1.07) 0.97 (0.94–1.01) 0.0285
Benzodiazepines 1.03 (0.99–1.08) 0.98 (0.94–1.02) 0.95 (0.91–0.99) 0.88 (0.84–0.92) 0.81 (0.77–0.84) 0.76 (0.73–0.79) o0.0001
Z-drugs 1.09 (1.04–1.14) 1.12 (1.08–1.17) 1.27 (1.22–1.32) 1.31 (1.26–1.37) 1.27 (1.22–1.32) 1.21 (1.16–1.26) o0.0001
Prevalences are compared to prevalence of those diagnosed in 2005. Logistic regression, unadjusted.
ap-Value for trend, Cochran–Armitage Trend test, year of diagnoses as continuous variable, 2-sided.
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Table 4 Most commonly purchased psychotropic drug
substances in the MEDALZ cohort one year after diag-
noses among persons with and without Alzheimer's
disease (AD).
Drug Persons with AD Persons without AD
N=69,080 N=275,021
N (%) N (%)
Antipsychotics
Risperidone 7738 (11.20) 3730 (1.36)
Quetiapine 4936 (7.15) 3045 (1.11)
Olanzapine 806 (1.17) 912 (0.33)
Haloperidol 712 (1.03) 704 (0.26)
Antidepressants
Mirtazapine 6689 (9.68) 10,564 (3.84)
Citalopram 6636 (9.61) 9856 (3.58)
Escitalopram 4942 (7.15) 4853 (1.76)
Venlafaxine 828 (1.20) 1318 (0.48)
Duloxetine 673 (0.97) 1265 (0.46)
Sertralin 643 (0.93) 1015 (0.37)
Amitriptyline 350 (0.51) 2325 (0.85)
Benzodiazepines and related drugs
Zopiclone 9587 (13.88) 38,145 (13.87)
Temazepam 5006 (7.25) 16,778 (6.10)
Oxazepam 4703 (6.81) 11,135 (4.05)
Lorazepam 1758 (2.54) 2944 (1.07)
Zopiclone 1459 (2.11) 7252 (2.64)
Diazepam 894 (1.29) 4321 (1.57)
1735High prevalence of psychotropic drug use among persons with and without Alzheimer's diseaseantipsychotic use among Finnish community-dwelling per-
sons diagnosed with AD was higher than reported in previ
ous studies from the UK and Germany. This may indicate
treatment practices favoring antipsychotic use although the
Finnish clinical care guideline on AD recommends antipsy-
chotic use only for severe BPSD symptoms (Finnish Medical
Society Duodecim, 2010).
We also found higher antidepressant consumption (28%)
among persons with AD than Martinez et al. (2013) (22%).
However, they found an increasing trend of antidepressant use
in those diagnosed in 1995–2011 and prevalence in 2011 (26%)
was almost similar to our ﬁndings. We did not ﬁnd changes in
antidepressant use during the years 2005–2011 except decreas-
ing use of tricyclics and SSRIs and corresponding increase in
use of “other antidepressants” like mirtazapine. Other pre-
vious studies (Guthrie et al., 2010; Rhee et al., 2011; Rattinger
et al., 2013) have reported antidepressant use in samples
including persons with differing times since diagnoses and
thus, are not directly comparable to our study including newly
diagnosed persons with AD.
BZDRs were the most commonly used psychotropic drugs
in our study with prevalence of 29% among persons with AD.
We also found almost similar prevalence (27%) among
persons without AD. Prevalence among persons with AD in
our study is much higher than reported by previous studies
in which 10% used hypnotics and 5% used anxiolytics
(Martinez et al., 2013). The frequent utilization of BZDRs
among persons with and without AD is concerning because
these drugs are associated with cognitive decline (Hanlon
et al., 1998; Paterniti et al., 2002) and an increased risk offalls among older persons (Cumming and Le Couteur, 2003;
Hartikainen et al., 2007). However, decline in prevalence of
BZDR use in 2005–2011 was an encouraging ﬁnding and may
imply more careful prescribing among persons with AD.
Among persons without AD, prevalence of BZDR use
increased until 2009 and then declined to the level than
observed in 2005. Further studies are needed to verify if this
declining trend was remained after 2011.
Antipsychotic use was six times more common and
antidepressant use three times more common among per-
sons with AD compared to persons without AD in our study.
Thus, our ﬁgures are similar to a previous study of anti-
psychotic use in persons with dementia compared to those
without (Schulze et al., 2013a, 2013b). We found more
frequent utilization of atypical antipsychotics whereas
Schulze and coworkers reported that conventional antipsy-
chotics were more commonly used. In our study, conven-
tional antipsychotic use declined and atypical antipsychotic
use increased according to year of AD diagnoses in 2005–
2011. Both conventional and atypical antipsychotics are
associated with an increased risk of stroke (Mittal et al.,
2011) but conventional antipsychotics are more likely to
cause serious adverse drug effects including anticholinergic
effects and parkinsonism (Byerly et al., 2001).
Antipsychotic use has also been associated with an
increased risk of death among older persons with and without
dementia (Schneider et al., 2005; Wang et al., 2005;
Schneeweiss et al., 2007; Ballard et al., 2009; Kales et al.,
2012; Gerhard et al., 2014). The risk has been associated
with both conventional and atypical antipsychotics but some
studies indicate higher risk for conventional antipsychotics
compared with atypicals (Wang et al., 2005; Gill et al., 2007;
Schneeweiss et al., 2007; Kales et al., 2012; Gerhard et al.,
2014). There may be differences between mortality risks
associated with different drug substances (Kales et al., 2012;
Gerhard et al., 2014) and there is some evidence of the dose–
response relationship on the risk of death (Gerhard et al.,
2014). The risk is pronounced especially at the initiation of
treatment (until 180 days) (Wang et al., 2005; Gill et al.,
2007; Schneeweiss et al., 2007; Kales et al., 2012; Gerhard
et al., 2014). Sustained risk in long-term use has been
reported in some studies (Ballard et al., 2009) whereas other
studies have not veriﬁed the risk in long-term use (Gardette
et al., 2012; Lopez et al., 2013). However, the assessment of
long-term effects is more challenging in terms of study
design. More studies with vigorous study design, control of
potential confounders, and with appropriate sample size to
ensure statistical power are needed. However, the risk–
beneﬁt ratio should be carefully evaluated based on the
current knowledge before starting antipsychotic drug use
among vulnerable persons with dementia.
In our study, antipsychotic use increased according to
year of AD diagnoses in 2005–2011. International warnings of
serious adverse drug events associated with antipsychotic
use in the treatment of BPSD were announced in 2005 and
2008 (FDA, 2005, 2008; EMA—European Medicines Agency,
2008). In our study, antipsychotic use remained stable in
2006–2007 compared to year 2005 but started to increase in
2008. This in contrast to previous ﬁndings in which declining
use of antipsychotics was reported among those diagnosed
in 1995–2011 (Martinez et al., 2013) and modest decline
after the safety warnings (Franchi et al., 2012). However,
H. Taipale et al.1736although Schulze et al. (2013b) found declining prevalence
of antipsychotic use in 2004–2009 at the same time the
deﬁned daily dose per treated patient increased. Reasons
for increasing antipsychotic use in Finland despite safety
warnings should be further investigated. Reasons may be
related to the lack of information on safety warnings,
difﬁculties to change treatment traditions or lack of alter-
natives for antipsychotics in treatment guidelines and
recommendations stated by the authorities.
As antipsychotic use increased, we found decline in
benzodiazepine and related drug use in 2005–2011 among
persons with AD. Declining BZDR use may indicate more
careful consideration of risks and beneﬁts among persons
with AD. It is possible that adverse events associated with
BZDRs, such as an increased risk of falls and daytime
sedation, are more likely to be observed in clinical practice
than adverse events associated with antipsychotic use.
However, the overall level of BZDR use in our study was
signiﬁcantly higher than in the previous studies (Guthrie
et al., 2010; Rhee et al., 2011; Martinez et al., 2013).
Psychotropic drugs were most commonly prescribed by
physician without specialty. In Finland, diagnoses of AD
involve geriatricians and neurologists but treatment after
diagnoses continues in general healthcare where physicians
without specialty represent the main proportion of prescri-
bers together with general practitioners.
Our nationwide cohort included all persons with new
clinically diagnosed AD in 2005–2011 and thus, our results
represent treatment practice among community-dwelling
persons in Finland. Further, we compared psychotropic drug
use of persons with AD to age-, gender- and region of
residence matched persons without AD. Drug data was
obtained from Prescription Register which represents actual
drug purchases instead of prescribed drugs and register-
based data is not object to recall or reporting bias compared
to self-reported data. Only reimbursed drug purchases are
recorded in the Prescription Register and some small
packages of BZDRs are not reimbursed. This limitation is
likely to underestimate exposure to BZDR drugs. Indications
for psychotropic drug use and severity of AD were not
included in our data which are limitations in our study.
In conclusion, we found widespread utilization of psycho-
tropic drugs among persons with AD. All psychotropic drug
classes were more frequently used by persons with AD although
prevalence of use among comparison persons without AD was
also signiﬁcant. The safety warnings related to antipsychotic
use among persons with dementia have not been effective as
we found an increasing trend of antipsychotic use among those
diagnosed in 2006–2011. High prevalence of antipsychotic and
BZDR use one year after AD diagnoses is concerning as both
have been associated with cognitive decline. The main goals in
the treatment of AD include preservation of cognitive function
and delay of institutionalization by maintaining functioning in
the activities of daily living (Finnish Medical Society Duodecim,
2010). Anti-dementia drugs are recommended for persons with
AD unless there is a contraindication for use. Initiation of anti-
dementia drug use takes place at the time of diagnoses and
thus, the follow-up time in our study represents also the
initiation and titration period of anti-dementia drugs. Thus,
frequent use of drugs associated with cognitive decline counter-
acts the preservation of cognitive function and maintenance of
functioning in activities of daily living.Role of funding source
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